Exited position

Seth Klarman’s Bristol-Myers Squibb Co (BMY) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Baupost GroupVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ1 2019Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares13.00MHighest verified quarter-end share count
Quarters reported4Verified quarters with shares above zero
What happened?

Baupost Group first reported Bristol-Myers Squibb Co in Q1 2019. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Baupost Group sold the entire position in Q1 2020, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q1 2020
Sold the entire position−4.00M shares · No shares reported at quarter-end
Q4 2019
Sold 60.0% of the position−6.00M shares · 4.00M shares remained
Filing context

Quarter-end price $64.19 · Estimated holding basis $46.08

Q3 2019
Sold 23.1% of the position−3.00M shares · 10.00M shares remained
Filing context

Quarter-end price $50.71 · Estimated holding basis $46.08

Q2 2019
Bought 225.0% more+9.00M shares · 13.00M shares reported after the change
Filing context

Quarter-end price $45.35 · Estimated holding basis $46.08

Q1 2019
New position+4.00M shares · 4.00M shares reported
Filing context

Quarter-end price $47.71 · Estimated holding basis $47.71

Portfolio importance

How important was Bristol-Myers Squibb Co in Baupost Group’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight2.8%Q4 2019
Last reported rank#9of 31 reported positions
Peak portfolio weight5.7%Q3 2019
Best historical rank#6Q3 2019
At peak importanceQ3 2019
BMY
5.7%
Largest holding
11.8%
Cross-investor discovery

Who else owns Bristol-Myers Squibb Co?

Also reported by 1 other tracked investor in their latest verified filings.

Joel GreenblattGotham Asset Management
BMY0.1% of reported portfolio
Explore Bristol-Myers Squibb Co across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$63.602026-09-16

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

This tracker follows Baupost Group LLC/MA’s Form 13F disclosures—not Seth Klarman’s personal brokerage account. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.